Sector News

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

May 15, 2022
Life sciences

The biggest biopharma acquisition of a drug company in 2021 has been delayed as antitrust reviews drag on.

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.

In its own statement, Vifor on Thursday said some antitrust authorities haven’t delivered a verdict. A Vifor spokesperson declined to specify which regulators remain undecided or whether any specific concerns have been raised. Rulings from the U.S. Federal Trade Commission, the European Competition Commission and the Swiss Takeover Board are all still pending, the Australia Financial Review reports.

Delays in the regulatory approval process are not unusual, Vifor noted. Vifor said the two firms are continuing to work with the remaining antitrust authorities, and CSL said it remains confident in completing the buyout.

Winning antitrust green lights represent the last hurdle in the Vifor acquisition. Back in March, CSL said (PDF) it had collected 74% of Vifor shares and therefore declared the tender offer successful. At the time, the Australian company said the antitrust review process was on track and it reconfirmed the mid-2022 deal closure timeline.

CSL has its eyes on Vifor’s kidney disease and iron deficiency offerings. CSL’s biotech business, CSL Behring, is currently heavily dependent on its immunoglobulin portfolio, which is facing some difficulties during the pandemic due to plasma collection constraints. Elsewhere, the company’s hereditary angioedema therapy Haegarda is under pressure from Takeda’s Takhzyro and BioCryst Pharma’s newly launched oral drug Orladeyo.

The Australian biotech also sells hemophilia B product Idelvion, and its hemophilia B gene therapy program, bought from uniQure, recently turned up positive results in a phase 3 trial.

Vifor itself had a setback since the CSL takeover’s announcement in December. The FDA recently rejected Akebia Therapeutics’ chronic kidney disease anemia therapy vadadustat. Vifor has a license to sell the drug through its Fresenius dialysis facilities and other third-party sites.

Vifor boasts 37 programs in development, which can give CSL’s own pipeline a 32% boost.

By Angus Liu

Source: fiercepharma.com

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.